All In Biotech

Drug Trial Radar · NCT05751967

Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis

A Prospective, Multi-center, Randomized, Double-blind, Placebo-controlled Study: Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis and an Inadequate Response to Ursodeoxycholic Acid

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Feb 22, 2023

Primary completion

Dec 1, 2027

Study completion Dec 1, 2027

Sponsor

Lead sponsor
Xijing Hospital of Digestive DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Current treatment guidelines recommend ursodeoxycholic acid (UDCA) as the first-line treatment for new-diagnosed primary biliary cholangitis (PBC) patients. However, up to 40% patients are insensitive to UDCA monotherapy, and evaluation of UDCA response at 12 months may result in long period of ineffective treatment. We aimed to develop a new criterion to reliably identify non-response patients much earlier. Recently, our team designed and validated a new early criterion for distinguishing high-risk PBC patients in a Chinese population for the first time. Our data indicated that PBC patients with ALP ≤ 2.5 × ULN, AST ≤ 2 × ULN, and TBIL ≤ 1 × ULN (Xi'an criterion) after 1 month UDCA treatment were likely to have better prognosis. It can be readily applied in the rapid identification of PBC patients who require additional therapeutic approaches. However, whether it is reasonable to apply it to the response definition of clinical research, and the guidance of PBC management and choice of second-line treatment, further research is needed.

Conditions

  • Primary Biliary Cholangitis

Interventions

  • Placebo Combined With Ursodeoxycholic AcidDrug

    1 tablet/ day

  • Fenofibrate Combined With Ursodeoxycholic AcidDrug

    200 mg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients with complete biochemical responseTime frame: 48 weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University General Hospital

    Tianjin, China · Recruiting

  • The second hospital of Lanzhou University

    Lanzhou, Gansu, China · Recruiting

  • Sun Yat-sen Memorial Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Ying han

    Xi'an, Shaanxi, China · Recruiting

  • Sichuan Provincial People's Hospital,

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.